Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
04/08/2026 11:47
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis Aug 4 (Reuters) - Pfizer PFE.N beat Wall Street estimates for second-quarter profit on Tuesday, driven by strong demand for its blood thinner, Eliquis.
On an adjusted basis, the company reported a profit of 77 cents per share, compared with analysts' estimates of 68 cents per share, according to data compiled by LSEG.
(Reporting by Mariam Sunny and Mrinalika Roy in Bengaluru; Editing by Anil D'Silva)
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma